Aptahem signs a non binding Term Sheet for development, manufacturing and distribution of Apta-1 for sepsis in Europe
Aptahem AB (publ) announce today that the company has signed an NBTS (non binding Term Sheet) with a mid-sized pharmaceutical company with head quarters in Europe. The NBTS relates to license terms for exclusive development, manufacturing and distribution of Apta-1 for treatment of sepsis in Europe. The company has decided to publish the information about the NBTS as the signing allows the other party a period to negotiate exclusively with Aptahem. More specific information will be made public if the the transaction will take place with the other party.
The signed NBTS includes license terms for the therapeutic area, geographical territory, sub-licensing rights, areas of responsibilities, cost allocation, development plan, pricing and financial terms between the parties for Apta-1. Overall, the terms offers the company’s counterpart an exclusive right to develop, manufacture and distribute Apta-1 in European countries for the treatment of sepsis.
The above mentioned information is based on the ongoing discussions between Aptahem and the counterpart. The company has decided to publicly announce the NBTS as the signing allows the counterpart a period, from the signing of the NBTS, to negotiate exclusively with Aptahem. The company does not guarantee that a final agreement will be signed with the counterpart within the set time frame, or at all. Further, Aptahem does not guarantee that a transaction will take place based on the current terms in the NBTS.
CEO Mikael Lindstam comments:
”We have had regular contact with our counterpart for over one year and the overall dialogue has now resulted in a more in-depth due diligence phase. Both parties agree that the need for new treatments for sepsis is huge, and that the properties of Apta-1 seem promising to create patient benefit. The European market is large and a partnership would be financially and strategically auspicious to commercialize Apta-1 in an optimal way, and I believe that there are good conditions for a prosperous collaboration.”
For further information:
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
This contains such information that Aptahem AB is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the above contact person for publication on 9 March 2021.
Sepsis is today considered a world health problem and affects 49 million people worldwide each year, of which 11 million die. In Europe alone, over 1 million people are estimated to be affected by sepsis on a yearly basis*. There is currently no specific treatment for sepsis, but instead the underlying symptoms are treated with antibiotics, fluids and oxygen.
* Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7. PMID: 31954465; PMCID: PMC6970225.
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.